Navigation Links
Genasense Plus Chemotherapy Is Associated With Prolonged Survival in Patients With Relapsed/Refractory CLL Who Achieve Complete Remission
Date:12/10/2007

therapy.

Genta has filed a currently pending appeal to the Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER), which seeks reconsideration of FDA's decision in December 2006 not to approve the use of Genasense in patients with relapsed/refractory CLL.

"The addition of Genasense to chemotherapy has resulted in a clinically meaningful survival benefit for patients who achieved CR," commented Dr. O'Brien. "These data strongly confirm the high degree of clinical benefit that accrues to patients who achieve CR. Achievement of CR remains an essential goal of CLL treatment."

"As one of the patients who remains in CR more than 4 years after receiving Genasense on this study, I strongly support the pending appeal of FDA's decision that declined to make this drug available to other patients who suffer from CLL," commented Thomas F. Mahoney, who entered the Phase 3 Genasense trial in 2002.

Genasense in CLL

In the Phase 3 trial, patients with relapsed or refractory CLL were randomly assigned to receive chemotherapy with fludarabine plus cyclophosphamide (Flu/Cy) with or without Genasense. This study - the only randomized controlled trial ever conducted in this population - achieved its intent-to-treat primary endpoint, which was a statistically significant increase in the proportion of patients who achieved a complete or nodular partial response (CR) (17% vs. 7%; P=0.025). By definition, CR represents the complete elimination of all clinical signs of leukemia, combined with the elimination of leukemia-related symptoms. In addition, the duration of CR - a prospectively specified and independent secondary endpoint -- was also significantly longer for patients treated with Genasense (median not yet reached but exceeding 36 months in the Genasense group compared with 22 months for patients treated with chemotherapy alone).

The data presented today are exploratory analyses based on extended follow-up of all pat
'/>"/>

SOURCE Genta Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
2. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
3. Authorization for AGENDA Phase 3 Trial of Genasense(R) in Advanced Melanoma Granted by French Regulatory Agency
4. Genasense(R) Can be Administered by Brief High-Dose IV Infusion
5. Genasense(R) Data in Patients with Advanced Melanoma to be Featured at 4th International Melanoma Congress
6. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
7. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
8. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
9. Tablet PC Technology Helps Doctors and Patients Focus on Chemotherapy Side Effects, According to Thomson Healthcare Study
10. Promising Data from Paratek Pharmaceuticals MAR Inhibitor Program Presented in Late Breaker Session at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
11. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... , July 22, 2014 The steady ... is spreading to previously rep-friendly specialties, according to ... and marketing consulting firm ZS Associates.      ... 200 U.S. pharmaceutical sales teams. The report examines ... meet with the pharmaceutical sales reps who visit ...
(Date:7/22/2014)... 22, 2014 BioDelivery Sciences International, Inc. (BDSI) ... of Directors has appointed Charles J. (Chuck) Bramlage ... members of the Board.  Mr. Bramlage ... in marketing, sales and other commercial functions.  He is ... a development stage company that was recently acquired by ...
(Date:7/22/2014)... 22, 2014  UL (Underwriters Laboratories), a global ... Food and Drug Administration (FDA) has recognized two ... medical devices incorporating lithium or nickel-based batteries. The ... Household and Commercial Batteries, and UL 1642 - ... Consensus standards are standards recognized by the FDA ...
Breaking Medicine Technology:Even traditionally rep-friendly specialists will see fewer pharmaceutical sales reps this year, according to ZS Associates 2Even traditionally rep-friendly specialists will see fewer pharmaceutical sales reps this year, according to ZS Associates 3Even traditionally rep-friendly specialists will see fewer pharmaceutical sales reps this year, according to ZS Associates 4Even traditionally rep-friendly specialists will see fewer pharmaceutical sales reps this year, according to ZS Associates 5BioDelivery Sciences Appoints Charles J. Bramlage and Dr. Barry I. Feinberg to its Board of Directors 2BioDelivery Sciences Appoints Charles J. Bramlage and Dr. Barry I. Feinberg to its Board of Directors 3BioDelivery Sciences Appoints Charles J. Bramlage and Dr. Barry I. Feinberg to its Board of Directors 4BioDelivery Sciences Appoints Charles J. Bramlage and Dr. Barry I. Feinberg to its Board of Directors 5BioDelivery Sciences Appoints Charles J. Bramlage and Dr. Barry I. Feinberg to its Board of Directors 6BioDelivery Sciences Appoints Charles J. Bramlage and Dr. Barry I. Feinberg to its Board of Directors 7Two UL Battery Safety Standards Are now FDA Recognized Consensus Standards for Medical Devices 2
... , RYE, N.Y., Oct. 14 Curemark, LLC, a drug ... diseases, announced that it has enrolled the first patients in ... The first clinical trial patients have been enrolled at Lake ... trial sites with a total 170 children across the country. ...
... Inc. (Nasdaq: VSCP ), a leading provider of quantitative ... the company,s chief business and financial officer, will be presenting ... Bio Investor Forum in San Francisco, California. Ms. Henderson is ... October 29, 2009 at the Palace Hotel, San Francisco. , ...
Cached Medicine Technology:Curemark Enrolls First Patients in Phase III Clinical Trials for Autism Treatment 2VirtualScopics to Present at the 8th Annual Bio Investor Forum 2
(Date:7/22/2014)... Today, Therapy Changes announces the start of their Teen ... help increase their knowledge and ability to cope with life’s ... to make healthy and positive decisions while connecting with like-minded ... but also a time of major life transition and stress,” ... . , “Teens can at times feel misunderstood, so rather ...
(Date:7/22/2014)... Quebec (PRWEB) July 22, 2014 ... is a set of simple tools, designed to help ... have little or no experience with biofeedback. The tools ... stressful situations and elucidate any abnormal patterns to teach ... today’s fast paced world, we are familiar with stress ...
(Date:7/22/2014)... Mass. (PRWEB) July 22, 2014 ... EBSCO Information Services , announces the launch ... assist occupational health and safety professionals employed by ... chemicals and need to manage the impact of ... PoisonEXPERT provides access to relevant chemical-specific information and ...
(Date:7/22/2014)... (PRWEB) July 22, 2014 The Muscular Dystrophy ... the third annual MUSCLE UP campaign that will ... more than one million Americans fighting muscle disease. ... to visit participating Jiffy Lube service centers through Sept. 1, ... to continue to make progress in the fight for muscle ...
(Date:7/22/2014)... (PRWEB) July 22, 2014 Brand ... landed MediaSource as a Ragan Communications 2014 Health ... will be the second consecutive year that MediaSource placed ... which was awarded to the winning MediaSource team last ... to keep this title against three other contenders that ...
Breaking Medicine News(10 mins):Health News:Therapy Changes Announces Teen Support Group Therapy 2Health News:Thought Technology to Present Software for Stress Control at the 2014 American Psychological Association Convention in DC 2Health News:Thought Technology to Present Software for Stress Control at the 2014 American Psychological Association Convention in DC 3Health News:PoisonEXPERT™ from ExPub Now Available 2Health News:PoisonEXPERT™ from ExPub Now Available 3Health News:Jiffy Lube® Supports Fight Against Muscle Disease with Third Annual MUSCLE UP® Campaign 2Health News:Jiffy Lube® Supports Fight Against Muscle Disease with Third Annual MUSCLE UP® Campaign 3Health News:MediaSource Brand Journalism Returns to Best Health Care Agency Competition in Ragan Communications Health Care Awards 2Health News:MediaSource Brand Journalism Returns to Best Health Care Agency Competition in Ragan Communications Health Care Awards 3
... to Serve Elective Cash Pay ... ... financial services for elective (cash pay) surgery, today,announced a leap forward in ... for bariatric surgeons, cash pay business.,Beginning July 1st, 2008, the BLISCare(SM) insurance ...
... chemotherapeutic agents remains a large problem. In some cases, ... cellular process known as translation, which is central to ... Pelletier and colleagues, at McGill University, Montreal, have identified ... cancer cells to standard anticancer chemotherapeutic agents. , In ...
... a healthier life, study finds , , THURSDAY, June 12 ... aging, a new study found. , Researchers at the ... 60 and older for use of sleeping aids, daytime ... quality, and sleep duration. Based on the results, 20.8 ...
... FDA on food safety , , THURSDAY, June 12 (HealthDay ... ongoing outbreak of salmonella-contaminated tomatoes has risen to 228 ... reported Thursday. , Also Thursday, Congressional investigators said the ... its own stated goals of protecting the nation,s food ...
... Pa., June 12 MEDRAD, INC., has ... PETNET Solutions,a fully owned subsidiary of Siemens ... health care providers to inject Fluorodeoxyglucose,(FDG) for ... an innovative, new way. The partnership will ...
... of Excellence (CCE), the,nation,s only practice-owned and physician ... slate and Board of Directors.,Effective immediately, J. Ike ... the interim President of CCE. In addition, Linda,Bosserman, ... Medical,Officer. Dr. Bosserman had previously served as CCE,s ...
Cached Medicine News:Health News:BLIS to Offer Coverage Through 'A' Rated Insurance Carrier 2Health News:BLIS to Offer Coverage Through 'A' Rated Insurance Carrier 3Health News:Better Sleepers Are 'Successful Agers' 2Health News:228 People in 22 States Sickened in Ongoing Salmonella-Tomato Outbreak 2Health News:228 People in 22 States Sickened in Ongoing Salmonella-Tomato Outbreak 3Health News:228 People in 22 States Sickened in Ongoing Salmonella-Tomato Outbreak 4Health News:228 People in 22 States Sickened in Ongoing Salmonella-Tomato Outbreak 5Health News:MEDRAD and PETNET Solutions Partner for Innovative FDG Delivery 2Health News:MEDRAD and PETNET Solutions Partner for Innovative FDG Delivery 3Health News:Cancer Clinics of Excellence (CCE) Announces Management and Board of Directors Slate at 1st Annual General Membership Meeting 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: